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Objectives: There is a need for markers to facilitate the diagnosis of preeclampsia, one of the 
most chief causes of maternal and infant mortality. Preeclampsia causes damage to the 
glomeruli and vascular endothelium in pregnant women. Podocalyxin is a sialoglycoprotein 
found in both glomeruli and vascular endothelium. In this study, we investigated the levels of 
podocalyxin in preeclampsia, and studied its potential to predict preeclampsia. 
Material and methods: Women admitted to the Health Sciences University Derince Training 
and Research Hospital, Department of Obstetrics and Gynecology between February–
November 2018 due to high direct blood and diagnosed with preeclampsia according to the 
2013 American College of Obstetricians and Gynecologists criteria were included in the 
study. The control group consisted of healthy volunteers having similar demographic 
features (gestational week, gravida, parity, and age) with the preeclampsia group. The main 
outcome variable was serum podocalyxin levels. 
Results: The mean (± SD) podocalyxin levels of the study and control groups were 124.15 
± 39.63 ng/mL and 71.47 ± 16.86 ng/mL, respectively (t = 7.845, p < 0.001). Using a cut-off 
of 91.7123, podocalyxin could predict preeclampsia with 90% sensitivity and 98% specificity. 
 
 
Furthermore, podocalyxin levels were significantly higher than the normotensive participants 
in both early (143.81 ± 51.96 ng/mL vs 75.35 ± 19.36 ng/mL) and late-onset (110.22 ± 19.11 
ng/mL vs 68.26 ± 14.13 ng/mL) preeclampsia (p < 0.001).  
Conclusions: Serum podocalyxin levels increase in preeclampsia. We conclude that 
podocalyxin is a candidate for predicting preeclampsia. 




Preeclampsia is a systemic disorder that may affect both the mother and the fetus. It 
can cause serious cardiorespiratory, neurologic, renal, hepatic, and hematologic complications 
[1]. Preeclampsia is the second most common cause of maternal mortality in Turkey [2]. 
According to the World Health Report 2015, approximately 830 women die every day due to 
complications ensuing during pregnancy or delivery; the number of women died in 2016 was 
reported as 303,000 [3].  
Preeclampsia increases fetal risks associated with stillbirth, neonatal death, 
intrauterine growth retardation, and premature birth [4]. In addition, it has been implicated in 
increasing post-partum hypertension and chronic kidney disease [5]. 
Preeclampsia directly damages the glomerular endothelium, consequently causing 
acute renal injury. Thus, angiogenic instability is a trigger factor for the damage of both 
podocytes and the endothelium in preeclampsia [6]. 
On the other hand, podocalyxin is a glomerular podocyte protein, also secreted from 
endothelial cells of other organs, which increases in the urine of preeclamptic women [7].  
Some studies have reported that podocyturia may be used to predict preeclampsia and 
determine its severity [8–10]. However, a recent study indicated podocalyxin in pregnant 
women could be detected with the ELISA kit and speculated it could be used as a predictive 
tool for early onset preeclampsia [7]. 
 
Objectives 
This study investigated whether podocalyxin can be used as a predictive tool in 
preeclampsia.  
 




This study was designed as a prospective case-control study. Study reporting was done 
per the STROBE guideline [11]. Written informed permission was obtained from all 
participants. The study protocol was approved by the Local Ethical Committee of Non-




This research was carried out in Kocaeli Obstetrics and Gynecology Department of 
Derince Training and Research Hospital between February–November 2018. 
 
Participants  
Participants of the study consisted of 41 preeclamptic and 42 healthy pregnant women. 
Seventeen early-onset preeclampsia patients and 24 late-onset preeclampsia patients were 
included in the study at our clinic during the study period. The preeclamptic group included 
patients applied to the obstetrics and gynecology emergency department of Health Sciences 
University Derince Training and Research Hospital. Preeclampsia patients were chosen 
according to the 2013 American College of Obstetricians and Gynecologists (ACOG) criteria. 
According to ACOG: Preeclampsia is defined as hypertension combined with proteinuria, or 
in absence of proteinuria, combined with at least one or more other findings including 
maternal organ dysfunction (elevated liver enzymes, haematological complications, renal 
insufficiency, neurological symptoms) and pulmonary edema. Hypertension is classified 
either as new onset hypertension after 20 weeks of gestation with blood pressure 
levels ≥ 140/90 mmHg on two occasions at least 4 h apart, or as chronic hypertension. Severe 
features of preeclampsia include blood pressure at least  ≥ 160/110 mm Hg, platelet count less 
than 100 × 103 per μL, liver transaminase levels two times the upper limit of normal, a 
doubling of the serum creatinine level or level greater than 1.1 mg per dL, severe persistent 
right upper-quadrant pain, pulmonary edema, or new-onset cerebral or visual disturbances. 
Normotensive healthy pregnant volunteers with similar gestational week, gravida, parity, and 
age as in the preeclampsia group constituted the control group. The control participants were 
pregnant women seen in the same center during the study period who had no high blood 
pressure during the follow-up, did not have any systemic disease, and did not use any drugs 
except vitamin and iron supplementations. All participants were at or beyond the 20th 
gestational week. Patients who had previously high blood pressure, renal or liver disease, 
 
 
intermittent hypertension, or proteinuria before pregnancy were excluded from the study (Fig. 
1). Detailed physical examination and routine blood tests were ordered in all patients. Patients 
were informed by the attending physician, and if approved, 5 mL blood was taken in addition 
to routine blood tests. Preeclampsia was diagnosed according to the 2013 American College 
of Obstetricians and Gynecologists (ACOG) criteria. 
 
Variables 
The primary outcome variable of the study was “serum podocalyxin level”. Secondary 
outcome variables were routinely ordered tests including serum ALT, AST, LDH, urea, 
creatinine, platelet count, urine protein/creatinine ratio, and 24-hour urine protein excretion. 
The routine tests were analyzed in the biochemistry laboratory of the hospital per hospital 
protocol. The blood obtained for podocalyxin analysis was centrifuged at 2500 rpm for 10 
minutes within 30 minutes after collection. The sera obtained were stored at -80 ° C until the 
time of analysis. Podocalyxin was studied using ELISA (Elabscience®, Hubei/China). Studies 
were carried out in accordance with the kit protocol. The ELISA kit used works with the 
competitive ELISA method. 
 
Study size 
The sample size was calculated based on the primary outcome variable with a 
minimum of 80% power and a maximum of 5% type 1 error to find a statistically significant 
difference between the study groups. The calculation with the power analysis of the E-picos 
section of the Medicres program revealed 37 participants in each group for a 95% confidence 
interval. Serum podocalyxin levels were assumed as 50 ± 12 ng/mL and 60 ± 12 ng/mL for 
normotensive healthy pregnant women and the preeclampsia group, respectively. 
 
Statistical Analysis 
The data were analyzed using the Statistical Package for the Social Sciences (SPSS) 
version 25.0 software (SPSS Inc., Chicago, IL, USA). The results of the study were presented 
as frequencies and percentages for categorical variables and as means and standard deviations 
for numerical variables. The normal distribution of the numerical variables was evaluated by 
checking the skewness coefficients. The independent samples t-test, Mann-Whitney U test, or 
one-way ANOVA were used to compare the groups in cases where parametric test conditions 
were met. Post hoc analyzes were performed with Tukey if the variances were homogeneous 
and Tamhane T2 if not. The receiver operating characteristics (ROC) analysis was used to 
 
 
determine sensitivity and specificity values for podocalyxin. Multivariate comparisons were 
examined by logistic regression analysis and two-way ANOVA. The statistical significance 
threshold was taken as p < 0.05. 
 
RESULTS 
Data for 83 participants were analyzed. Forty-one of them were preeclamptic, and 
forty-two were healthy pregnant. The mean age of the participants was 28.46 ± 5.28 years and 
range were between 18–40 (Tab. 1).  
According to urine dipstick results, 7 patients did not show proteinuria, 5 patients had 
trace proteinuria, 6 patients had +1 proteinuria, 13 patients had +2 proteinuria and 10 patients 
had +3 proteinuria. When podocalyxin levels were compared with the protein status in the 
urine, no statistically significant difference was detected (p = 0.417). 
 Podocalyxin, ALT, AST, LDH, urea, creatinine, systolic blood pressure, and diastolic 
blood pressure were significantly different in the preeclamptic (case) group compared to the 
controls. However, there was no significant difference in the urine protein/creatinine ratio and 
24-hour urine protein excretion (Tab. 2). Also, patients with early preeclampsia had 
significantly higher mean podocalyxin levels compared to those with late onset (143.81 ± 
51.96 ng/mL vs. 110.22 ± 19.11 ng/mL) (Mann-Whitney U Z = 2.435; p = 0.015). 
The ROC analysis demonstrated that podocalyxin provides a significant advantage in 
predicting preeclampsia (Area under the curve 0.939 p < 0.001) (Fig. 2). A podocalyxin cut-
off level of 91.71 provides 90% sensitivity and 98% specificity in foreseeing preeclampsia. 
Podocalyxin showed significant positive correlations with urea, creatinine, ALT, AST, 
and LDH (r; p 0.417; < 0.001, 0.372; 0.001, 0.226; 0.040, 0.327; 0.003, and 0.353; 0.001, 
respectively), and a significant negative correlation with platelet count (r = –0.373; p = 
0.001). 
A logistic regression analysis with preeclampsia status as the dependent and 
podocalyxin, and urea, creatinine, ALT, AST, LDH, and platelet levels as independent 
variables, demonstrated that podocalyxin was the only significant independent predictor of 






This study demonstrated that serum podocolyxin levels are increased in preeclamptic 
pregnancies. Cases with early onset had significantly higher podocalyxin levels compared 
with late onset. 
 
Limitations 
One limitation of this is the lack of Podocolyxin information of the participants before 
their pregnancies. Large-scale cohort studies are needed to calculate the odds of baseline 
podocalyxin levels in predicting preeclampsia.  
Interpretation 
 The diagnosis of preeclampsia, one of the most prominent causes of maternal and fetal 
morbidity and mortality, affecting 3–7% of healthy nulliparous and 1–3% of multiparous 
women, is of vital importance [12]. It was suggested that podocyturia screening at the end of 
the second trimester could identify pregnant women at risk for preeclampsia [13]. A study 
conducted in 2017, stated that serum podocalyxin values were higher in early preeclamptic 
pregnant women compared to a control group [7]. Our findings support this result and further 
add that the podocalyxin levels are significantly higher also in late-onset preeclampsia.  
 In other words, all preeclamptic pregnant women had higher podocalyxin levels. This 
finding is not surprising. Because the pathogenesis of preeclampsia, such as incomplete spiral 
artery remodeling that contribute to placental ischemia and release of antiangiogenic factors 
from the ischemic placenta to the maternal circulation causing endothelial damage, also affect 
podocalyxin levels. Additionally, the glomerular endothelium is directly damaged in 
preeclampsia, and podocalyxin is abundant in the renal glomeruli [14]. Podocalyxin is a 
glomerular podocyte protein, but it is secreted from endothelial cells of other organs too. We 
postulate that podocalyxin secreted from maternal endothelial cells may increase in the sera of 
preeclamptic women.  
 Preeclampsia occurs in 2–5% of pregnancies in developed countries. However, it may 
complicate up to 10% of pregnancies in developing countries, where emergency care may not 
be adequate [15]. In 2004, after conducting a systematic review of screening tests for 
preeclampsia, the World Health Organization reported that there was no clinically useful 
screening test to predict the development of preeclampsia in low-risk or high-risk populations, 
and advised for further studies [16]. After this report, many researchers have identified or 
examined potential biochemical and/or biophysical markers. Some systematic reviews and 
meta-analyzes evaluating the clinical benefits of studies with a single marker have been 
 
 
published [17–19]. However, the need for a suitable marker getting a high level of accuracy 
persisted [20].  
 To be effective, a screening test must be sufficiently sensitive and specific and provide 
an adequate positive predictive value. The argument that podocalyxin values can be used as a 
predictor in preeclampsia was noted as one of the essential findings of this study. For the first 
time serum podocalyxin was found to be successful in predicting preeclampsia at 90% 
sensitivity and 98% specificity. We want to speculate that the sensitivity and specificity of 
podocalyxin are high enough to suggest its involvement in preeclampsia diagnosis.  
 Although there are some conflicting studies, report generally support higher liver 
function tests in preeclamptic pregnant women [21–23]. According to a recent study, elevated 
AST and ALT levels in the first 20 weeks of pregnancy are associated with a higher risk of 
developing severe preeclampsia in the second half of the pregnancy. However, there is no 
clinical cut-off value that can be used practically to predict preeclampsia [24]. 
 In a study consisting of preeclampsia, severe preeclampsia, and control groups, 
hemoglobin values were lower in the patients with severe preeclampsia. However, ALT, AST, 
urea, and creatinine values too were significantly higher in this group [25]. In our study, no 
difference was found between the groups concerning hemoglobin values. In the preeclampsia 
group, ALT, AST, LDH, urea, and creatinine levels were significantly different from the 
control group, which was coherent with previous studies and expectations. However, it was 
surprising that there was no statistically significant difference in the urine protein/creatinine 
ratio and 24-hour urine protein excretion. This result was thought to be due to the low number 
of data on protein excretion in 24-hour urine. 
 In our study, preeclampsia was divided into two groups as early and late according to 
the time of onset. There was no statistically significant difference in other variables except 
podocalyxin in these two groups. This finding suggested that more focus should be placed on 
podocalyxin to elucidate the pathogenesis of preeclampsia. The remarkable point was that the 
level of podocalyxin was lower in late-onset preeclampsia than in the early-onset cases. In 
addition, there was no significant difference between severe preeclampsia and preeclampsia 
groups regarding podocalyxin levels. This suggests that podocalyxin is elevated 
independently of hypertension in preeclampsia. However, the low number of severe 
preeclampsia groups indicates that this result should be supported by larger studies. Probably 
endothelial damage is required to increase podocalyxin levels. Once damage occurs, its 
severity may not further increase podocalyxin levels. 
 
 
 Lactate dehydrogenase, the key enzyme of glycolysis, is used to identify the cause and 
location of tissue damage in the body and to help monitor the progress of the damage. LDH 
increases in many diseases as a result of its widespread distribution in the tissues [26]. On the 
other hand, podocalyxin has been reported to be a marker of embryonic hematopoietic stem 
cells (HSCs), erythroid cells and adult HSCs, and thus, may be a valuable marker for 
purification of these cells for transplantation [27]. It was suggested that the correlation 
between LDH and podocalyxin and the similarly their high levels in preeclamptic pregnant 
women can be attributed to the damage caused by preeclampsia. The correlation between 
LDH and podocalyxin, and heir surge in preeclamptic pregnant women may be due to the 
damage to tissues where both markers are dense. 
 
CONCLUSIONS 
 Serum podocalyxin levels are increased in preeclamptic pregnant women. The serum 
podocalyxin levels are higher in early onset preeclampsia compared to late onset cases. 
However, the severity of preeclampsia does not make a significant difference. We conclude 
that with 90% sensitivity and 98% specificity, podocalyxin is a candidate for 
predicting preeclampsia.  
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Figure 2. Receiver operating characteristics graph showing podocalyxin levels in predicting 






























Table 1. Demographic features of the participants 
  n Mean SD Minimum Maximum 
Age [year] 83 28.46 5.28 18 40 
Height [cm] 83 160.90 6.87 148 175 
Weight [kg] 83 86.65 16.62 57 130 
Hemoglobin [mg/dL] 83 11.37 1.26 8.40 14.90 
Hematocrit [%] 83 34.84 3.49 27.00 43.30 
Platelets [number/mL] 83 202.42 60.11 27 352 
ALT 83 19.55 35.53 6 234 
AST 83 23.67 23.74 10 173 
LDH 83 241.27 88.85 120 617 
Creatinine 83 0.56 0.07 0.43 0.88 




Table 2. Comparison of the preeclamptic and control groups concerning the outcome 
measures. 
 
Group N Mean SD *p 
t 
Podocalyxin [ng/mL] Preeclamptic 41 124.15 39.63 < 
0.001 
7.845 
Control 42 71.47 16.86   
Systolic blood pressure 
[mmHg] 
Preeclamptic 41 151.71 12.82 < 
0.001 
17.769 
Control 42 105.71 10.68   
Diastolic blood pressure 
[mmHg] 
Preeclamptic 41 98.54 6.54 < 
0.001 
17.724 
Control 42 68.69 8.62   
Urine protein / creatinine 
ratio 
Preeclamptic 21 2.43 4.13 0.054 2.036 
Control 7 0.52 0.66   
24-hour urine protein 
excretion [mg] 
Preeclamptic 8 2306.85 4367.97 0.529 0.658 
Control 2 181.50 86.97   
Platelets [number/mL] Preeclamptic 41 182.98 62.25 0.003 -3.056 
Control 42 221.40 51.95   
ALT Preeclamptic 41 28.83 48.88 0.018 2.389 
Control 42 10.50 4.92   
AST Preeclamptic 41 31.73 31.63 0.003 3.187 
Control 42 15.81 4.81   
LDH Preeclamptic 41 282.20 100.14 < 
0.001 
4.603 
Control 42 201.31 51.92   
Creatinine Preeclamptic 41 0.58 0.09 0.027 2.255 
Control 42 0.55 0.06   
Urea Preeclamptic 41 18.88 6.85 0.005 2.935 
Control 42 15.12 4.55   
 
 





   
 
 
 
 
 
